Scholarlink

Background <p>Diabetic Retinopathy (DR), a leading cause of preventable blindness, is conventionally evaluated using seven-field retinal fundus photography. Ultra-widefield fluorescein angiography (UWF FA) allows for detailed visualization and quantification of peripheral retinal non-perfusion (NP). This study aims to assess changes in NP and neovascularization (NV) following intravitreal anti-VEGF and steroid treatments using UWF FA.</p> Methods <p>This retrospective, single-center cohort study included 65 eyes from 45 patients with Type 1 or 2 diabetes mellitus (DM) and UWF FA images acquired across two visits. Images were manually segmented by masked, trained graders, annotating foveal avascular zone (FAZ), NP, and NV surface areas. Patient demographics, clinical history, and treatment details were extracted via chart review. Stepwise multivariate linear regression identified predictors of changes in FAZ, NP, and NV areas, while causal modeling estimated effects of anti-VEGF and steroid treatments over time.</p> Results <p>Eyes treated with steroid injections (<i>N</i> = 13) had decreased total and mid-periphery retinal NP areas compared to untreated eyes or eyes that received anti-VEGF alone (total change in NP area: 4.32 ± 24.66 vs. 32.30 ± 65.40 vs. 27.21 ± 42.09 mm<sup>2</sup>; <i>p</i> &lt; 0.05). Increased frequency of steroid injections predicted decreased FAZ area (<i>p</i> = 0.0036). Longer duration between FAs was associated with larger NP areas by 0.87 mm<sup>2</sup> per additional month (95% CI, 0.25 to 1.5; <i>p</i> = 0.0072), whereas more steroid injections (<i>p</i> = 0.035), DME on initial clinical presentation (<i>p</i> = 0.013), and vitreous hemorrhage development (<i>p</i> = 0.0002) were associated with decreased NP areas. Compared to eyes in type 1 diabetics, eyes with type 2 DM were associated with − 56.45 mm<sup>2</sup> smaller total NP areas over time (95% CI, -92.3 to -20.52; <i>p</i> = 0.0028). Causal analyses suggest each additional steroid injection was associated with a 31.38 mm<sup>2</sup> decrease in total NP area (95% CI, -58.14 to -4.62; <i>p</i> = 0.022). Anti-VEGF treatment (<i>N</i> = 28) did not have a significant effect on FAZ (95% CI, -0.153 to 0.060; <i>p</i> = 0.40), NP (95% CI, -17.20 to 3.91; <i>p</i> = 0.22), or NV areas (95% CI, -0.391 to 0.282; <i>p</i> = 0.75).</p> Conclusions <p>Compared to anti-VEGF, intravitreal steroids produced significant improvement in retinal perfusion. Quantitative biomarkers from UWF FA may provide an objective approach to assessing treatment response and DR severity over time.</p> Trial registration <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quantifying changes in retinal non-perfusion over time with ultra-widefield fluorescein angiography following intravitreal treatment of diabetic retinopathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月9日

查看全文
  • Callie Deng,
  • Karthik Reddy,
  • Yue Liang,
  • Nikhil Bommakanti,
  • Julie Rosenthal,
  • Yannis M. Paulus

摘要

Background

Diabetic Retinopathy (DR), a leading cause of preventable blindness, is conventionally evaluated using seven-field retinal fundus photography. Ultra-widefield fluorescein angiography (UWF FA) allows for detailed visualization and quantification of peripheral retinal non-perfusion (NP). This study aims to assess changes in NP and neovascularization (NV) following intravitreal anti-VEGF and steroid treatments using UWF FA.

Methods

This retrospective, single-center cohort study included 65 eyes from 45 patients with Type 1 or 2 diabetes mellitus (DM) and UWF FA images acquired across two visits. Images were manually segmented by masked, trained graders, annotating foveal avascular zone (FAZ), NP, and NV surface areas. Patient demographics, clinical history, and treatment details were extracted via chart review. Stepwise multivariate linear regression identified predictors of changes in FAZ, NP, and NV areas, while causal modeling estimated effects of anti-VEGF and steroid treatments over time.

Results

Eyes treated with steroid injections (N = 13) had decreased total and mid-periphery retinal NP areas compared to untreated eyes or eyes that received anti-VEGF alone (total change in NP area: 4.32 ± 24.66 vs. 32.30 ± 65.40 vs. 27.21 ± 42.09 mm2; p < 0.05). Increased frequency of steroid injections predicted decreased FAZ area (p = 0.0036). Longer duration between FAs was associated with larger NP areas by 0.87 mm2 per additional month (95% CI, 0.25 to 1.5; p = 0.0072), whereas more steroid injections (p = 0.035), DME on initial clinical presentation (p = 0.013), and vitreous hemorrhage development (p = 0.0002) were associated with decreased NP areas. Compared to eyes in type 1 diabetics, eyes with type 2 DM were associated with − 56.45 mm2 smaller total NP areas over time (95% CI, -92.3 to -20.52; p = 0.0028). Causal analyses suggest each additional steroid injection was associated with a 31.38 mm2 decrease in total NP area (95% CI, -58.14 to -4.62; p = 0.022). Anti-VEGF treatment (N = 28) did not have a significant effect on FAZ (95% CI, -0.153 to 0.060; p = 0.40), NP (95% CI, -17.20 to 3.91; p = 0.22), or NV areas (95% CI, -0.391 to 0.282; p = 0.75).

Conclusions

Compared to anti-VEGF, intravitreal steroids produced significant improvement in retinal perfusion. Quantitative biomarkers from UWF FA may provide an objective approach to assessing treatment response and DR severity over time.

Trial registration

Not applicable.